A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
Persistence to Treatment With Guselkumab in Bio-Naive Patients With Moderate-to-Severe Plaque Psoriasis: A Romanian Non-Interventional Multi-center Observational Study
- Psoriasis
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 200
- Started
- 15 May 2026
- Main results due
- 15 September 2028
- Study sites
- 20
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion criteria: * Has a confirmed diagnosis of moderate-to-severe plaque psoriasis * Participant must sign an informed consent form allowing source data verification in accordance with local requirements * Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments * No previous exposure to biological treatment, including guselkumab (bio-naive patient) * Intended for the treatment with guselkumab according to the approved indication Exclusion criteria: * Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC) * Is pregnant or lactating * Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product. * Currently enrolled in another observational study sponsored or managed by a Johnson \& Johnson company
What this study is about
In the sponsor’s own words, from the registry.
This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
Study sites(20)
Mihaila G. Georgiana - Cabinet Medical Individual Dermatovenerologie
Bârlad, Romania
Recruiting
Qualimed SRL
Brasov, Romania
Recruiting
Spitalul Universitar de Urgenta Elias, Clinica de Cardiologie
Bucharest, Romania
Recruiting
Spitalul Clinic Colentina 1
Bucharest, Romania
Recruiting
Spitalul Clinic Colentina
Bucharest, Romania
Recruiting
Alin Nicolescu Medic Primar Dermato Venerologie
Bucharest, Romania
Recruiting
OptiDerm Estet
Bucharest, Romania
Recruiting
Spitalul Clinic Judetean de Urgenta Cluj Napoca
Cluj-Napoca, Romania
Recruiting
Ambulator Specialitate Sp Militar de Urgenta Dr Constantin Papilian Cluj Napoca
Cluj-Napoca, Romania
Recruiting
Innovative Derm SRL
Constanța, Romania
Recruiting
MC Medica SRL
Craiova, Romania
Recruiting
Policlinica Dr.Corbeanu
Craiova, Romania
Recruiting
Policlinica Top Med Buna Vestire
Craiova, Romania
Recruiting
Derma Lux SRL
Iași, Romania
Recruiting
Spitalul Clinic Judetean de Urgenta Bihor
Oradea, Romania
Recruiting
Derma Lux SRL 1
Reghin, Romania
Recruiting
Evaderm Health SRL
Slatina, Romania
Recruiting
Spitalul Judetean de Urgenta 'Sf.Ioan cel Nou', Sectia Oncologie
Suceava, Romania
Recruiting
Clinica Cabimed
Targu Mureș, Romania
Recruiting
Dr Tirziu Dermato Chirurgie SRL
Timișoara, Romania
Recruiting
Showing 20 of 20 sites. 20 of the 20 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07582783. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me